FAP-Targeted CAR T Cells Reduced Fibrotic Burden in a Mouse Model of Pulmonary Fibrosis
Pulmonary fibrosis remains one of the most difficult chronic lung diseases to treat because the core problem is not just inflammation but the persistence of activated fibroblasts that keep laying down scar tissue. In this study, investigators turned to CAR T-cell therapy and asked whether an immune-engineered approach could do what current antifibrotic drugs cannot: remove the cells driving the scar itself.
The therapeutic target was fibroblast activation protein-α, or FAP, a molecule identified as highly and selectively expressed in myofibroblasts and fibroblasts within fibrotic lung tissue. Single-cell RNA sequencing pointed to FAP as a cell-surface marker concentrated in the very populations that sustain fibrosis. In practical terms, that matters because a surface target gives engineered T cells something they can recognize and attack directly, instead of trying to blunt a fibrotic program indirectly.
A single sentence captures the biological logic: the scar-producing cells became the target.
Why FAP Became the Therapeutic Entry Point
Fibrotic lung disease is progressive and irreversible once enough architectural distortion sets in. The disease is not driven by a single inflammatory burst but by ongoing activation of fibroblasts and myofibroblasts, which generate extracellular matrix and stiffen the lung parenchyma. Standard therapies can slow progression, but they do not eliminate the pathogenic fibroblast pool that keeps the process alive.
That gap provided the rationale for using a cell therapy platform that has already shown potency in hematologic malignancies and is now being explored in non-malignant disease. Here, the idea was straightforward: redirect T cells against FAP-expressing stromal cells and see whether fibrosis regresses. This is a more aggressive strategy than symptom control or pathway inhibition, because it attempts to remove a cellular engine of disease rather than merely dampen its output.
Mouse Data Linked FAP Expression to Fibrotic Lung Tissue
The work moved from human tissue profiling to an in vivo injury model. In bleomycin-induced mice, FAP upregulation appeared in fibroblast populations, confirming that the target seen in human fibrotic tissue was not an artifact of sequencing alone. That confirmation is important because any cell therapy aimed at a tissue-specific antigen depends on the antigen being present where the disease is active.
Once that expression pattern was established, the investigators generated murine CAR T cells designed to target FAP. The premise was not to broadly suppress immunity, but to focus immune killing on the pathogenic fibroblast compartment. In fibrotic lung disease, selective targeting is the difference between a mechanistically appealing concept and a clinically plausible therapy, because indiscriminate immune damage would be unacceptable in already compromised lungs.
Lung Function Improved Alongside Scar Reduction
Treatment with FAP-targeted CAR T cells significantly reduced fibrotic burden. It also improved pulmonary function, including mid-tidal expiratory flow (EF50), minute ventilation (MV), and tidal volume (TV). Those are not abstract laboratory readouts; they are functional signals that the lungs were moving air more effectively after the intervention.
The physiologic meaning is direct. As fibrosis stiffens the lung, ventilation becomes constrained and airflow dynamics worsen. If pathogenic fibroblasts are removed, tissue compliance can improve enough to alter ventilatory performance. In this model, the improvement in EF50, MV, and TV fits the biology of a lung made less rigid by a reduction in the cellular machinery of scarring.
Another short truth stands out: the intervention changed both tissue pathology and breathing mechanics.
What the Preclinical Signal Suggests About Disease Biology
This work supports a broader concept in fibrotic disease: the fibroblast is not just a passive responder but an active therapeutic target. By identifying FAP as selectively expressed in disease-relevant fibroblast populations, the study connects molecular profiling with cell therapy design. That kind of linkage matters because it narrows the target to cells most likely to perpetuate fibrosis while reducing the odds of missing the disease driver entirely.
The study also shows why CAR T technology has attracted interest beyond oncology. Engineered T cells can be programmed to seek out a defined surface antigen, and that precision creates an opportunity in non-malignant disorders where pathological cells are identifiable but difficult to eradicate with drugs. In pulmonary fibrosis, the challenge has always been that the lesions are built from the body’s own mesenchymal cells. A therapy that can selectively remove those cells offers a different route into the disease process.
At the same time, the biology raises obvious questions about selectivity and safety. FAP is attractive precisely because it is enriched in fibrotic fibroblasts, but any antigen shared with healthy stromal compartments would matter. The current data come from a mouse model, so translational success will depend on whether the same target distribution holds in human disease and whether the treatment can avoid injury to normal tissue repair pathways.
What Still Needs to Be Proven Before Clinical Use
This is a proof-of-concept study, not a clinical test in patients with pulmonary fibrosis. The findings show feasibility in a bleomycin-induced model and provide preclinical support for the idea that pathogenic fibroblasts can be removed by immune engineering. They do not yet establish durability, dose optimization, off-target toxicity, or how this approach would behave in chronic human fibrosis, where tissue remodeling is more heterogeneous than in a controlled animal model.
Open questions remain around persistence of the CAR T cells, the depth of fibroblast depletion required for meaningful disease modification, and whether repeated injury or ongoing fibrogenic signaling would simply recruit new fibroblasts after treatment. Human translation will also need to address whether a fibrotic lung can tolerate the inflammatory consequences of cell therapy without worsening respiratory failure.
Even so, the study offers a clear mechanistic advance: FAP-targeted CAR T cells were able to reduce fibrosis and improve lung function in a preclinical model by striking at the fibroblasts that sustain scar formation. The next hurdle is not whether the concept is biologically coherent, but whether it can be made safe and durable enough for patients with progressive pulmonary fibrosis.